Sung Ji Nam
Stock Analyst at Scotiabank
(2.54)
# 1,656
Out of 5,182 analysts
81
Total ratings
47.76%
Success rate
2.26%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $92.25 | -34.96% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $47.41 | +58.21% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $174.92 | +57.21% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $472.95 | +24.75% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $142.58 | -12.33% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $24.75 | +61.62% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $15.00 | +166.67% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $4.11 | +45.99% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.27 | +214.96% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.71 | +16.96% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $14.43 | -16.84% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $349.53 | +28.74% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $59.53 | +4.15% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $41.19 | +6.82% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $20.95 | +67.06% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $3.64 | +64.84% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.92 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $92.25
Upside: -34.96%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $47.41
Upside: +58.21%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $174.92
Upside: +57.21%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $472.95
Upside: +24.75%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $142.58
Upside: -12.33%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $24.75
Upside: +61.62%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $15.00
Upside: +166.67%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $4.11
Upside: +45.99%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.27
Upside: +214.96%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.71
Upside: +16.96%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $14.43
Upside: -16.84%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $349.53
Upside: +28.74%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $59.53
Upside: +4.15%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $41.19
Upside: +6.82%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $20.95
Upside: +67.06%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $3.64
Upside: +64.84%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.92
Upside: -